Inclusion Criteria:

- Histologically or cytologically confirmed prostate cancer with progressive disease

- Evidence of castration resistance defined as disease progression despite a
testosterone level < 50ng/dL (or surgical castration)

- Evidence of metastatic disease to the bones within the lumbar spine, sacrum, or
pelvic bones that is identifiable on screening pelvic MRI

- If patient has had prior pelvis radiation therapy (RT), then bone metastases must be
out of radiated port (e.g. lumbar or sacral spine)

- Any prior therapy for castrate disease acceptable other than prior XL184 with a
minimum washout of 28 days for any other anticancer therapy

- Patients with castrate resistant disease post antiandrogen therapy/withdrawal must
meet at least one of the following criteria:

- Have not received docetaxel chemotherapy

- Have received docetaxel chemotherapy but received less then 225mg/m2 cumulative
dose

- Have documented liver metastases

- Have no pain or pain that does not require a long acting (SR) narcotic

- Have received mitoxantrone chemotherapy in the past for CRPC

Exclusion Criteria:

- Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering
the study

- Patients who are receiving any other investigational agents

- Prior treatment with other vascular endothelial growth factor (VEGF) or c-MET
targeted therapies

- History of hematemesis or hemoptysis

- The subject has uncontrolled or significant intercurrent illness

- The patient requires concomitant treatment, in therapeutic doses, with anticoagulants